Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Public ClinicalTrials.gov record NCT03834766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT03834766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- AMPH ER Tab 5, 10, 15 and 20 mg Drug
- AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2019
- Primary completion
- Oct 18, 2019
- Completion
- Oct 18, 2019
- Last update posted
- Nov 1, 2023
2019
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Meridien Research | Bradenton | Florida | 344201 | — |
| Meridien Research, Inc. | Maitland | Florida | 32751 | — |
| Center for Psychiatry and Behavioral Medicine | Las Vegas | Nevada | 89128 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03834766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2023 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03834766 live on ClinicalTrials.gov.